In the latest session, Transmedics Group Inc (NASDAQ: TMDX) closed at $82.03 down -2.05% from its previous closing price of $83.75. In other words, the price has decreased by -$1.72 from its previous closing price. On the day, 592056 shares were traded.
Ratios:
For a deeper understanding of Transmedics Group Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.49 and its Current Ratio is at 9.30. In the meantime, Its Debt-to-Equity ratio is 3.76 whereas as Long-Term Debt/Eq ratio is at 3.75.
On August 02, 2022, JP Morgan Upgraded its rating to Overweight which previously was Neutral but kept the price unchanged to $48.
JP Morgan Downgraded its Overweight to Neutral on October 08, 2020, while the target price for the stock was maintained at $15.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 04 ’24 when Gordon Stephen sold 15,000 shares for $82.80 per share. The transaction valued at 1,242,000 led to the insider holds 25,202 shares of the business.
TOBIN JAMES R sold 13,380 shares of TMDX for $1,118,955 on Mar 01 ’24. The Director now owns 220,211 shares after completing the transaction at $83.63 per share. On Mar 01 ’24, another insider, Khayal Tamer I, who serves as the Chief Commercial Officer of the company, sold 10,000 shares for $82.99 each. As a result, the insider received 829,892 and left with 26,502 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMDX now has a Market Capitalization of 2.74B and an Enterprise Value of 2.86B. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.11 while its Price-to-Book (P/B) ratio in mrq is 19.53. Its current Enterprise Value per Revenue stands at 11.85 whereas that against EBITDA is -371.68.
Stock Price History:
Over the past 52 weeks, TMDX has reached a high of $99.63, while it has fallen to a 52-week low of $36.42. The 50-Day Moving Average of the stock is 84.10, while the 200-Day Moving Average is calculated to be 72.12.
Shares Statistics:
For the past three months, TMDX has traded an average of 567.67K shares per day and 1M over the past ten days. A total of 32.67M shares are outstanding, with a floating share count of 31.47M. Insiders hold about 3.80% of the company’s shares, while institutions hold 108.99% stake in the company. Shares short for TMDX as of Feb 15, 2024 were 4.93M with a Short Ratio of 8.69, compared to 5.42M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 15.07% and a Short% of Float of 17.44%.
Earnings Estimates
There are 3 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.07 for the current quarter, with a high estimate of $0.11 and a low estimate of -$0.33, while EPS last year was -$0.08. The consensus estimate for the next quarter is -$0.05, with high estimates of $0.28 and low estimates of -$0.37.
Analysts are recommending an EPS of between -$0.41 and -$1.24 for the fiscal current year, implying an average EPS of -$0.82. EPS for the following year is -$0.06, with 3 analysts recommending between $1.55 and -$0.9.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $83.9M this quarter.It ranges from a high estimate of $85.5M to a low estimate of $81.2M. As of the current estimate, Transmedics Group Inc’s year-ago sales were $41.55M, an estimated increase of 101.90% from the year-ago figure.
A total of 6 analysts have provided revenue estimates for TMDX’s current fiscal year. The highest revenue estimate was $372.4M, while the lowest revenue estimate was $360M, resulting in an average revenue estimate of $367M. In the same quarter a year ago, actual revenue was $241.62M, up 51.90% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $488.48M in the next fiscal year. The high estimate is $539.8M and the low estimate is $450.14M. The average revenue growth estimate for next year is up 33.10% from the average revenue estimate for this year.
